

Christina Lake Cannabis Corp.
Condensed Interim Financial Statements
For the three and six months ended May 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

NOTICE OF NO AUDITOR REVIEW

Under National Instrument 51-102, Part 4 subsection 4.3 (3), if an auditor has not performed a review of the unaudited condensed interim financial statements, they must be accompanied by a notice indicating that the unaudited condensed interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements of Christina Lake Cannabis Corp. have been prepared by and are the responsibility of management.

These unaudited condensed interim financial statements for the six months ended May 31, 2023 have not been reviewed or audited by the Company's independent auditors in accordance with standards established by the Chartered Professional Accountants of Canada.

Christina Lake Cannabis Corp.
Condensed Interim Statements of Financial Position
(Expressed in Canadian Dollars - Unaudited)

As at,	Notes	May 31, 2023 (unaudited) \$	November 30, 2022 (audited) \$
ASSETS			
Current assets			
Cash		1,531,378	1,810,639
Investments		1	28,750
Receivables		2,183,575	1,906,820
Prepaid expenses		19,432	3,885
Inventory	5	4,144,802	5,766,418
		7,879,188	9,516,512
Non-current assets			
Property, plant and equipment	3	9,112,218	9,277,906
TOTAL ASSETS		16,991,415	18,794,418
LIABILITIES			
Current liabilities			
Accounts payable and accrued liabilities	6,11	1,300,378	1,132,447
GST payable		39,713	76,451
Current portion of loans	9	893,617	897,632
Current portion of convertible debentures	8	3,929,825	3,726,424
		6,163,533	5,832,954
Non-current liabilities			
Government loan	7	37,360	34,947
Non-current portion of loans	9	190,923	581,329
Convertible debentures	8	1,373,468	1,207,228
TOTAL LIABILITIES		7,765,284	7,656,458
SHAREHOLDERS' EQUITY			
Share capital	12	22,499,898	22,403,648
Equity component of convertible debenture	8	1,872,441	1,872,441
Obligation to issue shares	12	113,250	113,250
Reserves		2,695,706	2,742,105
Deficit		(17,955,165)	(15,993,484)
TOTAL SHAREHOLDERS' EQUITY		9,226,131	11,137,960
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		16,991,415	18,794,418

Nature and continuance of operations (Note 1)

Approved on behalf of the Board:

"James McMillan"

James McMillan, Director

"Gil Playford"

Gil Playford, Director

Christina Lake Cannabis Corp.
Condensed Interim Statements of Loss and Comprehensive Loss
(Expressed in Canadian Dollars - Unaudited)

	Notes	Three-month period ended,		Six-month period ended,	
		May 31, 2023	May 31, 2022	May 31, 2023	May 31, 2022
		\$	\$	\$	\$
Revenue from sale of goods	16	3,476,740	2,321,010	5,393,905	3,973,811
Cost of sales	5	(1,784,554)	(1,027,348)	(3,085,255)	(1,772,279)
Gross profit before fair value adjustments		1,692,186	1,293,662	2,308,650	2,201,532
Changes in fair value of inventory sold	5	(1,192,006)	(441,941)	(1,681,269)	(669,282)
Gross profit from sale of goods/change on growth of biological assets		500,180	851,721	627,381	1,532,250
General and administrative expenses					
Consulting fees	11	43,054	10,500	88,056	104,829
Communication expense		38,408	31,297	60,692	49,400
Corporate development		-	-	-	8,864
Depreciation	3	66,038	43,599	211,845	210,537
Foreign exchange		-	5,774	-	5,774
Insurance		20,037	36,421	40,180	80,165
Management fees	11	16,064	78,192	60,952	139,821
Marketing		-	1,603	2,385	44,966
Office and miscellaneous		130,129	141,625	235,413	251,785
Professional fees	11	137,987	101,644	206,316	190,569
Property Taxes		5,919	28,366	5,919	28,366
Salaries	11	397,808	308,477	915,638	759,458
Share based compensation	11,12	27,948	105,201	49,850	246,950
Research & Development		14,798	-	20,312	-
Repairs and maintenance		23,719	50,356	54,513	110,089
Regulatory fees		78,136	26,218	145,380	54,635
Total general and administrative expenses		(1,000,045)	(969,273)	(2,097,451)	(2,286,208)
Other items					
Accretion	7,8,10	(70,404)	(344)	(144,505)	(84,046)
Interest expense	8	(204,482)	(119,200)	(369,555)	(214,905)
Loss on sale of equipment		-	-	-	-
Fair value of preferred shares		-	-	-	-
Accounts payable write down		-	-	-	-
Gain on settlement	12	-	258,767	-	258,767
Total other items		(274,886)	139,223	(514,060)	(40,184)
Loss and comprehensive loss for the period		(774,751)	21,671	(1,984,130)	(794,142)
Loss per share – basic and diluted		(0.01)	(0.00)	(0.02)	(0.01)
Weighted average number of common shares outstanding		130,959,845	126,355,885	130,959,845	126,355,885

The accompanying notes are an integral part of these financial statements

Christina Lake Cannabis Corp.
Condensed Interim Statement of Changes in Shareholders' Equity
For the six months ended May 31, 2023 and 2022
(Expressed in Canadian Dollars - Unaudited)

	Share capital		Obligation to issue shares \$	Equity component of convertible liability \$	Reserves \$	Deficit \$	Total \$	
	Common shares							
	Note	Number of shares #						Amount \$
Balance at November 30, 2021		115,891,174	19,457,649	113,250	418,080	2,703,270	(12,953,060)	9,739,189
Loss for the period		-	-	-	-	-	(769,565)	(769,565)
Shares issued upon exercise of options	12	700,000	204,669	-	-	(141,669)	-	63,000
Share based compensation	12	-	-	-	-	95,501	-	95,501
Balance at February 28, 2022		116,591,174	19,662,318	113,250	418,080	2,657,102	(13,722,625)	9,128,125
Balance at November 30, 2022		130,872,174	22,403,648	113,250	1,872,441	2,742,105	(15,993,484)	11,137,960
Loss for the period		-	-	-	-	-	(1,984,130)	(1,984,130)
Shares issued upon vesting of restricted shares	12	250,000	96,250	-	-	(96,250)	-	-
Share based compensation	12	-	-	-	-	35,602	-	35,602
Balance at May 31, 2023		131,122,174	22,499,898	113,250	1,872,441	2,681,457	(17,977,614)	9,189,432

The accompanying notes are an integral part of these financial statements

Christina Lake Cannabis Corp.
Condensed Interim Statements of Cash Flows
(Expressed in Canadian Dollars - Unaudited)

Six-month period ended,	May 31, 2023	May 31, 2022
	\$	\$
Operating activities		
Loss for the period	(1,984,130)	(794,142)
Non-cash items:		
Accretion	144,505	83,702
Depreciation	211,845	266,812
Fair value transfer of inventory sold	1,681,269	669,282
Interest expense	369,555	95,705
Share-based compensation	49,850	246,950
Changes in non-cash working capital items:		
Increase in receivables	(353,215)	39,276
Decrease in prepaid expenses	(15,547)	(42,031)
Decrease(increase) in inventory	155,009	210,374
Increase in accounts payable and accrued liabilities	148,918	(94,332)
Net cash flows provided by operating activities	407,861	681,596
Investing activities		
Acquisition of equipment	(229,211)	(18,248)
Building improvements incurred	(7,789)	41,242
Proceeds from sale of equipment	-	-
Net cash flows used in investing activities	(237,000)	22,994
Financing activities		
Loan payments	(450,122)	(324,442)
Loan Proceeds		2,000,000
Repayment of Preferred Share Obligation		(4,858,767)
Shares issued in Preferred Share Conversion		2,600,000
Lease payments	-	(4,651)
Proceeds from options exercised	-	67,590
Net cash flows from financing activities	(450,122)	(520,270)
Increase (decrease) in cash	(279,261)	184,320
Cash, beginning of year	1,810,639	1,075,666
Cash, end of period	1,531,378	1,259,986
Supplemental non-cash flow information:		
	May 31, 2023	May 31, 2022
Six-month period ended,	\$	\$
Interest paid	-	-
Taxes paid	-	-

The accompanying notes are an integral part of these financial statements

1. Nature and continuance of operations

Christina Lake Cannabis Corp. (the “Company”) was incorporated on October 26, 2014, under the laws of the province of British Columbia, Canada. The Company is a licensed producer of cannabis in British Columbia under the Cannabis Act with a standard cultivation, processing and sales license and a research and development license. On October 1, 2020, the Company began trading on the Canadian Securities Exchange under the ticker symbol “CLC” and on the OTC Markets Group Inc. under the ticker symbol “CLCFF.”

The Company’s principal address, records office and registered address are located at Suite 810 – 789 West Pender Street, Vancouver, BC, V6C 1H2.

These financial statements have been prepared on the assumption that the Company will continue as a going concern, meaning it will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations. As at May 31, 2023, the Company had accumulated losses of \$17,955,165 (2022 - \$15,993,484). The Company’s continuation as a going concern is dependent upon the Company to successfully obtain debt or equity financings and harvest its cannabis and earn revenues from the sale of cannabis related derivatives to meet current and future obligations and ultimately achieve profitable operations. These factors indicate the existence of a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern. Management intends to successfully harvest and sell cannabis related derivatives to achieve profitability from its business activities. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence. Such adjustments could be material.

2. Significant accounting policies

Basis of presentation

These condensed interim financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) on a historical cost basis except for financial instruments that have been measured at fair value. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting except for cash flow information.

These condensed interim financial statements have been prepared on an historical cost basis, except for financial instruments which are classified as fair value through profit or loss. In addition, these condensed interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information. All amounts on the condensed interim financial statements are presented in Canadian dollars which is the functional currency of the Company.

These unaudited condensed interim financial statements were approved and authorized for issue on July 27, 2023 by the directors of the Company.

Statement of compliance

These condensed interim financial statements, including comparatives, have been prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” (“IAS 34”) using accounting policies consistent with the International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”) and Interpretations of the IFRS Interpretations Committee.

These unaudited condensed interim financial statements do not include all of the information required of a full annual financial report and is intended to provide users with an update in relation to events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period. It is therefore recommended that this financial report be read in conjunction with the audited financial statements of the Company for the year ended November 30, 2022.

Functional and presentation currency

In management's judgement, the functional currency of the Company is the Canadian dollar. The presentation currency used in preparing these financial statements of the Company is also the Canadian dollar.

Significant estimates and assumptions

The preparation of the Company's financial statements in conformity with IFRS requires management to make estimates and assumptions concerning the future. Estimates and assumptions are continuously evaluated and are based on management's experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. However, actual outcomes can differ from these estimates.

Areas requiring a significant degree of estimation relate to the fair value measurements for financial instruments and biological assets, discount rate on lease liability, convertible debentures, loan and preferred shares, assumptions used in the cash flow projection for preferred shares, useful lives and valuation of property, plant and equipment, valuation of inventory and the recoverability and measurement of deferred tax assets and liabilities. Actual results may differ from those estimates.

Management is required to make a number of estimates in calculating the fair value less costs to sell of biological assets. These estimates include a number of assumptions such as estimating the stage of growth of the cannabis, harvesting costs, sales price, and expected yields.

Significant judgments

The preparation of financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company's financial statements include: the classification of expenditures as building improvements to be capitalized or as operating costs which are expensed; discount rate used for right of use assets; the assessment of the Company's ability to continue as a going concern and whether there are events or conditions that may give rise to a significant uncertainty.

Recent Accounting Pronouncements

As at the date of authorization of these financial statements, the IASB and the IFRIC had issued certain pronouncements that are mandatory for the Company's accounting periods commencing on or after December 1, 2022. Many are not applicable or do not have a significant impact to the Company, have been excluded. The Company had assessed that no material impact is expected upon the adoption of the following amendments on its financial statements:

Amendments to IAS 1

In January 2020, the IASB issued amendments to IAS 1 which clarify the requirements for classifying liabilities as either current or non-current by: (i) specifying that the conditions which exist at the end of the reporting period determine if a right to defer settlement of a liability exists; (ii) clarifying that settlement of a liability refers to the transfer to the counterparty of cash, equity instruments, other assets or services; (iii) clarifying that classification is unaffected by management's expectation about events after the balance sheet date; and (iv) clarifying the classification requirements for debt an entity may settle by converting it into equity. These amendments are effective for annual periods beginning on or after January 1, 2023.

Amendments to IAS 37 – Provisions, Contingent Liabilities and Contingent Assets (“IAS 37”)

In May 2020, the IASB issued amendments to update IAS 37. The amendments specify that in assessing whether a contract is onerous under IAS 37, the cost of fulfilling a contract includes both the incremental costs and an allocation of costs that relate directly to contract activities. The amendments also include examples of costs that do, and do not, relate directly to a contract. These amendments are effective for annual periods beginning on or after January 1, 2022.

Christina Lake Cannabis Corp.
Notes to the condensed interim financial statements
For the six months ended May 31, 2023 and 2022
(Expressed in Canadian Dollars - Unaudited)

3. Property, plant and equipment

Property, plant and equipment are comprised of the following balances:

	Right-of- use asset \$	Equipment \$	Land \$	Building \$	Building improvement \$	Total \$
Cost						
Balance at November 30, 2021	59,924	3,864,139	1,088,397	394,875	5,499,917	10,907,252
Additions	-	1,009,914	-	-	85,269	1,095,183
Balance, November 30, 2022	59,924	4,874,053	1,088,397	394,875	5,585,186	12,002,435
Additions	-	489,861	-	-	7,789	497,650
Balance, May 31, 2023	59,924	5,363,914	1,088,397	394,875	5,592,975	12,500,085
Accumulated amortization						
Balance at November 30, 2021	50,448	951,704	-	-	360,527	1,362,679
Change	9,476	1,055,225	-	-	297,149	1,361,850
Balance, November 30, 2022	59,924	2,006,929	-	-	657,676	2,724,529
Change	-	528,513	-	-	134,825	663,338
Balance, May 31, 2023	59,924	2,535,442	-	-	792,501	3,387,867
Net book value						
November 30, 2022	-	2,867,124	1,088,397	394,875	4,927,510	9,277,906
May 31, 2023	-	2,828,472	1,088,397	394,875	4,800,474	9,112,218

The right-of-use asset relates to leased equipment for the production and cultivation of cannabis. The lease is reflected on the balance sheet as a right-of-use asset, with an associated lease liability (Note 10). The discount rate applied to the lease is 8%.

During the period ended May 31, 2023, the Company capitalized depreciation of \$356,163 (2022 - \$99,874) as inventory processing cost and \$Nil (2022 - \$Nil) as biological asset cost.

4. Biological assets

Biological assets are comprised of:

	Amount \$
Balance at November 30, 2020	-
Changes in fair value less cost to sell due to biological transformation	3,240,450
Production cost capitalized	1,732,191
Transferred to inventory upon harvest	(4,972,641)
Balance at November 30, 2021	-
Changes in fair value less cost to sell due to biological transformation	4,641,853
Production cost capitalized	2,242,286
Transferred to inventory upon harvest	(6,884,139)
Balance at November 30, 2022 and May 31, 2023	-

Measurement of the biological transformation of the plant at fair value less costs to sell and less incremental processing costs post-harvest is recognized at the point of harvest.

The Company has determined that conversion of plants to distillate is the highest and best use. The Company has determined the fair value less costs to sell and less incremental processing costs of cannabis distillate to be \$2.06 per gram of distillate. The average harvested yield of biomass is 1,774 grams per plant with an average yield from dried biomass to distillate of 6 to 9% depending on strains.

Christina Lake Cannabis Corp.
Notes to the condensed interim financial statements
For the six months ended May 31, 2023 and 2022
(Expressed in Canadian Dollars - Unaudited)

The fair value of biological assets is determined using a valuation model to estimate expected yield per plant applied to the estimated selling price per gram less incremental processing and selling costs. Only when there is a material change from the expected fair value used for cannabis does the Company make any adjustments to the fair value used.

Sales price used in the valuation of biological assets is based on the average selling price of cannabis distillate products and can vary on the proportion of sales derived from wholesale sales. Selling costs vary depending on methods of selling and are considered based on the expected method of selling and the determined additional processing costs which would be incurred. Expected yields for the cannabis plant is also subject to a variety of factors, such as strains being grown, length of growing cycle, and designated planting area or density. Management reviews all significant inputs based on historical information obtained.

The following table highlights the sensitivities and impact of changes in significant assumptions on the fair value of biological assets grown at outdoor facility:					
Significant inputs & assumptions	Range of inputs		Sensitivity	Impact on fair value	
	November 30, 2022	November 30, 2021		November 30, 2022	November 30, 2021
Average selling price per gram	\$3.00	\$3.80	Increase or decrease of \$0.25 per gram	\$836,250	\$551,500
Average yield per plant (grams)	1774	1,540	Increase or decrease of 5% in yield per plant	\$324,825	\$369,140
Average yield to distillate from biomass (dependent on strain)	6-9%	5-7%	Increase or decrease of distillate yield by 5%	\$501,750	\$419,667

These inputs are level 3 on the fair value hierarchy and are subject to volatility in market prices and several uncontrollable factors, which could significantly affect the biological transformation to inventory upon harvest.

5. Inventory

Inventory is comprised of cannabis biomass and derivatives:

	Amount \$
Balance at November 30, 2021	7,153,378
Capitalized cost	3,465,110
Harvested cannabis biomass	6,884,139
Inventory write-down	(2,471,436)
Cost of sales	(5,937,128)
Changes in fair value of inventory sold	(3,327,645)
Balance at November 30, 2022	5,766,418
Capitalized cost	3,144,908
Cost of sales	(3,085,255)
Changes in fair value of inventory sold	(1,681,269)
Balance at May 31, 2023	4,144,802

During the period ended May 31, 2023, the Company recorded \$3,144,908 (2022 - \$1,561,905) of production costs.

Christina Lake Cannabis Corp.
Notes to the condensed interim financial statements
For the six months ended May 31, 2023 and 2022
(Expressed in Canadian Dollars - Unaudited)

As at May 31, 2023, the Company held the following inventory:

	May 31, 2023 \$	November 30, 2022 \$
Work-in-process	3,062,274	4,910,459
Finished goods	1,082,528	855,959
	4,144,802	5,766,418

6. Accounts payable and accrued liabilities

	May 31, 2023 \$	November 30, 2022 \$
Accounts payable	1,017,045	487,175
Accrued liabilities	283,333	645,272
	1,300,378	1,132,447

7. CEBA Loan

The Company entered into a Canada Emergency Business Account “CEBA” loan with the Government of Canada.

The loan is an interest free loan of \$40,000 from the Government of Canada. If the CEBA loan is repaid by December 31, 2023, 25% being \$10,000 will be forgiven. If the Company is not able to repay, the loan will convert into a regular loan with a three-year term at 5% per annum. Upon initial recognition, the Company recorded a gain on government loan of \$15,309. During the period ended May 31, 2023, the Company recorded accretion expense of \$2,413 (2022 - \$1,026).

8. Convertible debentures

Convertible debenture issued in 2022

On September 8, 2022 and October 18, 2022, the Company closed a non-brokered private placement of unsecured convertible debentures in the principal amount of \$810,000 and \$150,000, respectively. The debentures mature in 36 months from the date of issuance and bear interest at the rate of 15% per annum, with such interest to be accrued on a monthly basis and paid on a semi-annual basis. Pursuant to the terms of the debentures, the subscribers may at any time prior to the maturity date convert the principal amounts of the debentures and any accrued but unpaid interest into common shares of the Company, at a price of \$0.15 per common share. \$300,000 of unsecured convertible debentures were subscribed by directors and officers of the Company.

On September 8, 2022 and October 18, 2022, the Company issued 405,000 and 75,000 bonus warrants to the subscribers of the offering, respectively. Each subscriber received one half of one bonus warrant for each \$1 subscribed under the offering. Each bonus warrant is exercisable until December 31, 2024 to acquire one additional common share per bonus warrant at an exercise price of \$0.20 per share. The bonus warrants are subject to an acceleration clause, whereby if the volume weighted average price of the Company's common shares exceeds \$0.40 per common share for a period of 20 days, the Company may accelerate the expiry of the bonus warrants by providing notice to the holders.

In connection with the first tranche of the private placement, the Company paid a finder's fee of \$9,000 in cash.

The convertible debenture is a compound financial instrument. Management estimated the fair value of the debt using a discount rate of 20% applicable to the Company's business, with the residual value allocated to the equity components of the convertible debenture.

The residual value was allocated between the warrants and the conversion feature using the relative fair value method. The Black Scholes Pricing Model was used to determine the fair value of the warrants and conversion feature. For the warrant fair value, the inputs for the pricing model were stock prices between \$0.115 and \$0.13, and exercise price of \$0.20, expected life between 2.22 and 2.32, volatility between 106% and 114% and a risk-free rate of 3.57% to 4.13%. For the conversion feature, the inputs for the pricing model were a stock price stock prices between \$0.115 and \$0.13, and exercise price of \$0.15, expected life of 3 years, volatility between 106% and 114% and a risk-free rate of 3.57% to 4.13%.

Convertible debenture issued in 2020

During the year ended November 30, 2020, the Company closed six tranches of unsecured convertible debenture financings ("Debentures") with an aggregate face value of \$5,000 each. The Debentures bear interest of 12%, maturing in 24 months and the principal and interest are convertible into common shares at a conversion price of \$0.20 per common share, at the option of the debenture holders.

During the year ended November 30, 2021, a portion of the Debentures were converted to shares and 5,936,000 shares were issued, extinguishing \$1,052,224 in principal debt and related interest.

Management estimated that the fair value on initial recognition of the Debentures using a discount rate of 20% with the residual value allocated to the equity component of the Debentures.

On March 13, 2022, the Company amended the terms of the following Debentures:

- 358 Debentures issued on March 13, 2020 in the principal amount of \$1,790,000;
- 158 Debentures issued on March 23, 2020 in the principal amount of \$790,000;
- 20 Debentures issued on April 7, 2020 in the principal amount of \$100,000;
- 5 Debentures issued on May 14, 2020 in the principal amount of \$25,000;
- 50 Debentures issued on May 25, 2020 in the principal amount of \$250,000; and
- 38.5 Debentures issued on August 20, 2020 in the principal amount of \$192,500.

On August 18, 2022, the Company amended the terms of an additional 12.4 Debentures issued on August 20, 2020 in the principal amount of \$62,000.

The amended terms are as follows:

- Term extension from 24 months to 42 months
- Change in interest payable from a non-pro rata basis for year one and a pro rata basis for year two to a non-pro rata basis for the full term. All interest payable shall be convertible into common shares at a price of \$0.20 per common share, with an amount equals to unpaid interest for the period from last payment date to the maturity date, regardless of the date of conversion.

Due to the amendment to the terms of the Debentures, the Company is deemed to have extinguished the existing debentures and reissued new debentures with the new terms. The Company valued the liability and conversion feature of the new debentures at \$3,590,918 and \$1,782,4287 respectively.

Christina Lake Cannabis Corp.
Notes to the condensed interim financial statements
For the six months ended May 31, 2023 and 2022
(Expressed in Canadian Dollars - Unaudited)

The following table reconciles the recorded value of the liability component:

	2022 Convertible debenture \$	2020 convertible debenture \$	Total \$
Balance, November 30, 2021	-	3,765,682	3,765,682
Additions	860,987	3,590,918	4,451,905
Repayment	-	(31,000)	(31,000)
Extinguishment	-	(3,942,563)	(3,942,563)
Interest expense	30,859	386,308	417,167
Accretion expense	6,622	265,839	272,461
Balance, November 30, 2022	898,468	4,035,184	4,933,652
Interest expense	35,507	97,076	132,583
Accretion expense	7,906	69,164	77,070
Balance, May 31, 2023	941,881	4,201,424	5,143,305
Current portion	-	3,929,825	3,929,825
Non-current portion	898,468	271,599	1,170,067

The following table reconciles the recorded value of the equity component:

	2022 equity component \$	2020 equity component \$	Total \$
Balance, November 30, 2021	-	418,080	418,080
Additions	90,013	1,782,428	1,872,441
Extinguishment	-	(418,080)	(418,080)
Balance, November 30, 2022 and May 31, 2023	90,013	1,782,428	1,872,441

9. Loan payable

During the year ended November 30, 2022, the Company entered into a loan agreement in connection with the redemption and cancellation of the Class B Preferred Shares for \$2,000,000 (Note 12). The loan bears simple interest at 8% per annum and matures August 31, 2024 with security of equipment and land of the Company. Upon issuance of the loan, the Company repaid one of the loan holder \$250,000 principal and \$48,384 interest for the entire term. Therefore, the additions of the loan is higher than its face value.

	\$
Balance, November 30, 2021	-
Additions	2,210,533
Accretion	(78,404)
Repayments	(673,384)
Interest paid in cash	(128,301)
Interest	141,023
Balance, November 30, 2022	1,471,467
Repayments	(450,122)
Interest	55,701
Balance, May 31, 2023	1,077,046
Current portion	893,617
Non-current portion	183,429

Christina Lake Cannabis Corp.
Notes to the condensed interim financial statements
For the six months ended May 31, 2023 and 2022
(Expressed in Canadian Dollars - Unaudited)

During the year ended November 30, 2020, the Company entered into a loan agreement to purchase equipment for \$15,640. The loan does not bear interest and matures in four years.

	\$
Balance, November 30, 2020	14,337
Repayments	(3,910)
Balance, November 30, 2021	10,427
Repayments	(2,933)
Balance, November 30, 2022 and May 31, 2023	7,494
Current portion	4,887
Non-current portion	2,607

10. Lease liability

During the year ended November 30, 2020, the Company entered into lease agreements to lease a loader and generator for a period of 2 years. The Company recognized right-of-use asset of \$59,924 and lease liability of \$59,924.

At the commencement date of the lease, the lease liability was measured as the present value of the future lease payments that were not paid at that date. These lease payments are discounted using a discount rate of 8%, which is the Company's estimated incremental borrowing rate.

The following is a continuity schedule of lease liabilities for the period ended February 28, 2023 and for the year ended November 30, 2022:

	\$
Balance, November 30, 2021	4,651
Lease payments	(7,800)
Accretion on lease liability	3,149
Balance, November 30, 2022 and May 31, 2023	-
	-

11. Related party transactions and balances

The Company has identified its directors and certain senior officers as its key management personnel.

As at May 31, 2023, there was \$83,882 (2022 - \$348,035) included in accounts payable and accrued liabilities for related parties of the Company. The balances are unsecured, due on demand and are non-interest bearing.

As at May 31, 2023, the Company has an obligation to issue 500,000 shares (2022 - 500,000 shares) to the former CEO in lieu of cash for consulting fees in the amount of \$113,250 (2022 - \$113,250) earned in prior years (Note 12).

Christina Lake Cannabis Corp.
Notes to the condensed interim financial statements
For the six months ended May 31, 2023 and 2022
(Expressed in Canadian Dollars - Unaudited)

During the period, the Company entered into transactions with related parties comprised of directors, officers and companies with common directors. The key management compensation and director fees consist of the following for the period ended May 31, 2023 and May 31, 2022:

	May 31, 2023 \$	May 31, 2022 \$
Consulting fees paid to an officer of the Company	60,952	77,143
Equipment purchase/lease to a company controlled by a director	55,650	13,000
Management fees paid to the CFO	-	51,250
Management fees and rent paid to former CEO	-	72,000
Salaries and bonus paid to key management	219,501	53,308
Share based payments	36,733	49,307
	<u>372,836</u>	<u>316,008</u>

12. Share Capital

Authorized share capital

Unlimited number of common shares without par value.

Unlimited number of Class B preferred shares without par value.

Issued share capital

At May 31, 2023, there were 131,122,173 (2022 – 129,892,173) issued and fully paid common shares outstanding.

At May 31, 2023, there were Nil (2022 - Nil) issued and fully paid Class B preferred shares outstanding.

Preferred shares

During the year ended November 30, 2020, the Company closed a preferred share private placement for total proceeds of \$2,000,000 (“Preferred Share Capital”). The Company paid finder’s fees in cash of \$15,302 and issued 1,000,000 finder’s shares with a fair value of \$300,000 to Leede Jones Grable Inc., providing strategic advisory services to the Company related to the preferred share private placements.

The following terms apply to the Preferred Shares:

Cumulative dividends on the Preferred Shares shall accrue and become payable in arrears on a monthly basis, for a period of 48 months, based on the following calculation:

- Repayment of Preferred Share Capital: 40% of the total revenue received by the Company from the sale of cannabis oil, hemp oil and other such hemp and cannabis derivative extracts produced by the Company, less the cost of any third-party feedstock (the “Product Revenue”), up to cumulative aggregate Product Revenue of \$5,000,000; It shall be payable as a capital repayment of the Preferred shares; and
- Preferred Share Dividend: for cumulative aggregate Product Revenue exceeding \$5,000,000, immediately following the repayment of Preferred Share Capital, the Company shall accrue on a monthly basis an amount equal to the sum of: (A) \$80 per kilogram of dry cannabis produced and processed by the Company from its own feedstock; and (B) an amount equal to 35% of Product Revenue derived from third party feedstock.

Christina Lake Cannabis Corp.
Notes to the condensed interim financial statements
For the six months ended May 31, 2023 and 2022
(Expressed in Canadian Dollars - Unaudited)

The payment of all accrued and accumulated dividends shall be postponed for that portion of Product Revenue attributable to uncollected revenue (the “Revenue Receivable”) and the balance of the postponed accrued and accumulated dividend shall become payable in the month where the Revenue Receivable is received by the Company. No dividend shall accrue or be payable after 4 years from the date of issuance. The preferred shares are secured by certain production equipment.

The preferred shares have been classified as liability at amortized cost due to the requirement for the Company to deliver cash during the term of the agreement. At inception, the Company determined that the effective interest rate of this financial liability was 20%.

The amortized cost of preferred shares at November 30, 2021 was estimated based on the following assumptions:

- Estimated annual production capacity of approximately 35,000 kilograms of dry biomass which is highly dependent on weather conditions for growing;
- Estimated A grade distillate yield of approximately 5-7%;
- Lead time of approximately 4-5 months to process the biomass to distillate oil;
- The estimated sales price of distillate oil is between \$3,500 and \$3,900 per kilogram; and
- Payment based on 90-day delay on cash conversion cycle.

During the year ending November 30, 2022, the Company redeemed 2,000,000 of the Class B preferred shares. In connection with the redemption the Company issued a secured promissory note in the amount of \$2,000,000 which bears an interest rate of 8% per annum and matures on August 31, 2024 (Note 9). The Company also issued 13,000,000 common shares with a fair value of \$2,470,000. On the date of settlement, the fair value of the Class B preferred shares at the transaction date was \$4,976,949 and the Company recorded a change in preferred share fair value of \$118,182. After the issuance of the above noted promissory note and common shares, the Company recorded a gain on settlement in the amount of \$296,416.

The following is a continuity schedule for preferred shares as at November 30, 2022:

	\$
Balance, November 30, 2020	3,620,098
Change in estimate of preferred shares	1,238,670
Balance, November 30, 2021	4,858,767
Change in estimate of preferred shares	118,182
Balance on the date of settlement	4,976,949
Secured promissory note issued for redemption	(2,210,533)
Shares issued for preferred share redemption and cancellation	(2,470,000)
Gain on settlement	(296,416)

Share issuances during the period ended May 31, 2023

During the period ended May 31, 2023, the Company issued 250,000 shares pursuant to restricted stock unit exercises. The Company transferred \$96,250 from reserve to share capital.

Share issuances during the year ended November 30, 2022

On October 19, 2022, the Company issued 730,000 common shares pursuant to the various warrant exercises for gross proceeds of \$65,700.

During the year ended November 30, 2022, the Company issued 751,000 common shares pursuant to stock option exercise for gross proceeds of \$67,588. The Company transferred \$150,211 from reserve to share capital.

Christina Lake Cannabis Corp.
Notes to the condensed interim financial statements
For the six months ended May 31, 2023 and 2022
(Expressed in Canadian Dollars - Unaudited)

During the year ended November 30, 2022, the Company issued 500,000 shares pursuant to restricted stock unit exercises. The Company transferred \$192,500 from reserve to share capital.

During the year ended November 30, 2022, the Company issued 13,000,000 common shares pursuant to the redemption and cancellation of the Class B Preferred Shares with a fair value of \$2,470,000.

Escrow Shares

As at May 31, 2023, a total of 4,191,205 (2022 – 8,601,413) securities, including 3,344,641 shares (2022 – 6,908,284), 767,064 warrants (2022 – 1,534,129), 79,500 (2022 – 159,000) stock options and nil(2022 – nil) convertible debentures, are held in escrow.

On October 1, 2020, the date on which the Company was listed on Canadian Securities Exchange (“Listing Date”), 2,302,761 common shares were released from escrow. The remaining 20,724,853 common shares would be released pursuant to the following schedule:

On the Listing date	1/10 of the escrow securities
6 months after the Listing Date	1/6 of the remaining escrow securities
12 months after the Listing Date	1/5 of the remaining escrow securities
18 months after the Listing Date	1/4 of the remaining escrow securities
24 months after the Listing Date	1/3 of the remaining escrow securities
30 months after the Listing Date	1/2 of the remaining escrow securities
36 months after the Listing Date	the remaining escrow securities

Warrants

The continuity of the Company's share purchase warrants pursuant is as follows:

	Number of share purchase warrants #	Weighted average exercise price \$
Outstanding, November, 30, 2021	14,994,677	0.44
Granted (Note 8)	480,000	0.20
Exercised*	(730,000)	0.09
Expired	(1,175,200)	0.21
Outstanding, November, 30, 2022	13,569,477	0.47
Expired	(9,751,301)	0.43
Outstanding, May 31, 2023	3,818,176	0.59

*The share price at the time of warrant exercise was \$0.115 per share.

As of May 31, 2023, the Company had share purchase warrants outstanding and exercisable to acquire common shares of the Company as follows:

Expiry date	Exercise price \$	Number of warrants, issued and exercisable #
December 8, 2023	0.65	3,338,176
December 31, 2024	0.20	480,000
		3,818,176

**9,751,301 Warrants expired unexercised during the period ended May 31, 2023.

Stock Options

On March 1, 2017, the Board of Directors approved the adoption of a fixed Stock Option Plan reserving for issuance, upon the exercise of options granted pursuant to the Stock Option Plan, a maximum of 20% of the issued and outstanding shares of the Company, less any shares required to be reserved with respect to options granted by the Company prior to the implementation of the Stock Option Plan. The Stock Option Plan was subsequently replaced with the 2018 Plan which was approved by shareholders at its January 9, 2019 Annual General and Special Meeting. The 2018 Plan is substantively similar to the Stock Option Plan except that it increases the number of common shares reserved under it. The 2018 Plan reserves 8,158,321 common shares (which represents 20% of the Company’s outstanding common shares as of the record date for the Meeting), compared to 199,520 under the Stock Option Plan.

Stock options granted during the year ended November 30, 2022.

On August 10, 2022, the Company granted 150,000 options to an employee, with a total fair value of \$15,165, to acquire one additional common share of the Company at a price of \$0.15 per share until August 10, 2027. These stock options vest quarterly over a 2-year period from the date of grant. The fair value was determined using the Black Scholes Option Pricing Model with the following assumptions: Expected life – 3.55 years; risk-free rate – 2.91%; volatility: 101%. During the year ended November 30, 2022, the Company recorded share-based compensation of \$5,884. During the period ended February 28, 2023, the Company recorded share-based compensation of \$3,395.

On June 20, 2022, the Company granted 1,000,000 options to an officer, with a total fair value of \$79,112, to acquire one additional common share at a price of \$0.12 until June 20, 2027. These stock options vest quarterly over a 2-year period from the date of grant. The fair value was determined using the Black Scholes Option Pricing Model with the following assumptions: Expected life – 3.55 years; risk-free rate – 3.35%; volatility: 97%. During the year ended November 30, 2022, the Company recorded share-based compensation of \$40,214. During the period ended February 28, 2023, the Company recorded share-based compensation of \$14,235.

On March 15, 2022, the Company granted 375,000 options to employees (“Employee Stock Options”) and 300,000 stock options to a director of the Company (“Director Stock Options”). The Employee Stock Options and Director Stock Options have exercise prices of \$0.25 and \$0.20, respectively, and expire on March 15, 2027. The total fair value of the options was \$69,072 and was determined using the Black Scholes Option Pricing Model with the following assumptions: Expected life – 3.55 years; risk-free rate – 1.94%; volatility: 76%. The Employee Stock Options vested immediately and half of the Director Stock Options vested immediately, with the remaining vesting on March 15, 2023. During the year ended November 30, 2022, the Company recorded share-based compensation of \$64,401. During the period ended February 28, 2023, the Company recorded share-based compensation of \$4,276.

The Black-Scholes Option Pricing Model was used with the following assumptions:

	Six months ending May 31, 2023	Year ending November 30, 2022
Exercise price	\$0.12 to \$0.25	\$0.12 to \$0.25
Expected life	3.55 years	3.55 years
Volatility	76% to 101%	76% to 101%
Risk-free-rate	1.94% to 3.35%	1.94% to 3.35%

Christina Lake Cannabis Corp.
Notes to the condensed interim financial statements
For the six months ended May 31, 2023 and 2022
(Expressed in Canadian Dollars - Unaudited)

The continuity of the Company's share purchase options is as follows:

	Number of share purchase options #	Weighted average exercise price \$
Outstanding, November 30, 2021	11,674,000	0.17
Granted	1,825,000	0.16
Exercised	(751,000)	0.09
Cancelled/expired/forfeited	(1,265,000)	0.12
Outstanding, November 30, 2022	11,483,400	0.18
Outstanding, May 31, 2023	11,483,400	0.18

The weighted average fair value of options granted during the year ended November 30, 2022 was \$0.09 (2021 - \$0.60). The weighted average price of shares at the time the options were exercised during the year ended May 31, 2023 was \$0.18 (2022 - \$0.18).

As of May 31, 2023, the Company had share purchase options outstanding and exercisable to acquire common shares of the Company as follows:

Expiry date	Exercise price \$	Number of options outstanding #	Number of options exercisable #
June 1, 2024	0.09	2,270,000	2,270,000
December 13, 2024	0.09	363,400	363,400
August 20, 2024	0.09	2,000,000	2,000,000
August 20, 2024	0.25	400,000	400,000
August 20, 2025	0.20	100,000	100,000
August 20, 2025	0.25	150,000	150,000
August 20, 2025	0.15	1,650,000	1,650,000
August 20, 2025	0.09	100,000	100,000
September 8, 2024	0.25	300,000	300,000
September 29, 2025	0.20	850,000	850,000
November 26, 2025	0.40	1,100,000	1,100,000
January 8, 2026	0.88	200,000	200,000
May 4, 2026	0.61	175,000	175,000
March 15, 2027	0.25	375,000	375,000
March 15, 2027	0.20	300,000	300,000
June 20, 2027	0.12	1,000,000	375,000
August 10, 2027	0.15	150,000	56,250
		11,483,400	10,764,650

Restricted share units ("RSUs")

On April 19, 2021, the Board of Directors approved the adoption of a RSUs Plan reserving for issuance, upon the vesting of units granted pursuant to the RSUs Plan, a maximum of 20% of the issued and outstanding shares of the Company, including the Company's stock option plan.

On September 30, 2021, the Company granted 1,000,000 RSUs to the President of the Company. 250,000 of the RSUs vested immediately upon issuance, with the balance to vest in three increments of 250,000 over 18 months. The RSUs were priced at \$0.385 based on the closing price of the common shares on the Canadian Securities Exchange on September 29, 2021. The total fair value of the RSUs was \$385,000. As at May 31, 2023, the Company has recognized \$Nil (2022 - \$28,181) in share based compensation.

On March 15, 2022, the Company issued an aggregate of 200,000 RSUs to a director of the Company in accordance with the Company's RSU plan. The RSUs vest upon various agreed upon milestones and entitle the holder the ability to acquire one common share of the Company underlying each such RSU by delivering a notice of acquisition to the Company in accordance with the RSU plan. The total fair value of the RSU was \$40,000. During the year ended November 30, 2022, the Company recognized share-based compensation of \$34,247.

As of May 31, 2023, the Company has 200,000 RSUs outstanding, of which 200,000 remains exercisable.

Reserve

The reserve account records items recognized as stock-based compensation expense and the fair value of finders' warrants issued until such time that the stock options and warrants are exercised, at which time the corresponding amount will be reallocated to share capital.

Obligation to issue shares

During the year ended November 30, 2021, the Company recorded an obligation to issue 500,000 shares to the former CEO in lieu of cash for consulting fees totalling \$113,250 (2021 - \$113,250). These 500,000 shares had not been issued as at May 31, 2023 and were included in obligation to issue shares.

13. Financial instruments

Fair value

Cash is carried at fair market value based on quoted market prices in an active market. The carrying value of accounts payable approximate its fair values due to the short-term nature of these financial instruments. Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

- Level 1 – unadjusted quoted prices in active markets for identical assets and liabilities;
- Level 2 – inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
- Level 3 – inputs that are not based on observable market data.

Cash and investments are measured using level 1 inputs. Biological assets are measured using level 3 inputs.

The Company determined that the carrying values of its short-term financial assets and liabilities approximate the corresponding fair values because of the relatively short periods to maturity of these instruments and the low credit risk.

The carrying value of the Company's convertible debentures approximates fair value as the liability component was discounted using an estimated market rate. The carrying value of long-term debts where interest is charged at a fixed rate is not significantly different than fair value.

13. Financial risk and capital management

The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is provided as follows:

Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk is on its cash held in bank accounts and accounts receivable. The majority of cash is deposited in bank accounts held with a major bank in Canada. As most of the Company's cash is held by one bank there is a concentration of credit risk. This risk is managed by using major banks that are high credit quality financial institutions as determined by rating agencies. Credit risk related to cash is assessed as low.

The Company provides credit to certain customers in the normal course of operations. Credit risk is generally limited to receivables from arm's length customers. The Company's credit risk related to its receivables is moderate. At May 31, 2023, the Company had no material receivable balances past due and the balances were collected subsequent to May 31, 2023. The Company has established monitoring processes to mitigate credit risk related to receivables.

Foreign exchange risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company is not exposed to foreign exchange risk.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company's normal operating requirements on an ongoing basis. The Company ensures that there are sufficient funds to meet its short-term business requirements, taking into account its anticipated cash flows from operations and its holdings of cash. As of May 31, 2023, the Company has cash of \$1,531,378 (2022 - \$1,810,639) to cover short term obligations.

Historically, the Company's source of funding has been through operations, loans from related parties, convertible debentures, preferred share financings and private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding. Liquidity risk is assessed as moderate.

Christina Lake Cannabis Corp.
Notes to the condensed interim financial statements
For the six months ended May 31, 2023 and 2022
(Expressed in Canadian Dollars - Unaudited)

The Company has the following contractual obligations as at May 31, 2023, which are expected to be payable in the following respective periods:

	Total		≤ 1 year	Over 1 year – 3 years		
Accounts payable	\$	1,300,378	\$	1,300,378	\$	-
GST payable		39,713		39,713		-
Loan payable		1,084,540		893,617		190,923
Government loan		37,360		-		37,360
Convertible debentures		5,303,293		3,929,825		1,373,468
Total	\$	7,765,284	\$	6,163,533	\$	1,601,751

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. As at May 31, 2023, the Company has government loan of \$37,360 (2022 - \$34,947) and an equipment purchase loan of \$7,494 (2022-\$7,494), which bear nil interest rates, convertible debentures of \$5,303,293 (2022 - \$4,933,652) and a secured loan of \$1,084,540 (2022 – \$1,471,467), which bear fixed interest rates respectively. As such, the Company’s interest rate risk is low.

Price risk

Price risk is the risk that the future cash flows of cannabis related derivatives will fluctuate because of changes in market prices. Fluctuation in price will significantly impact the demand for the Company’s products and the Company’s ability to generate cash inflow for its sustainable operation. Sensitivity analysis in Note 4 illustrates the impact of price changes in the fair value of biological assets, which in the end effects the value of the Company’s cannabis related derivatives.

Capital Management

The Company's policy is to maintain a strong capital base so as to maintain investor and creditor confidence and to sustain future development of the business. The capital structure of the Company consists of equity and cash. There were no changes in the Company's approach to capital management during the year. The Company is not subject to any externally imposed capital requirements.

15. Segment information

Operating segment

The Company operates in a single reportable operating segment –cultivation and production of cannabis related derivatives.

Geographic segment

The Company’s operation is based solely in Canada.

16. Revenue

For the six months ended May 31, 2023 and 2022, the following revenue was recorded from wholesale customers that comprise 10% or more of revenue:

	May 31, 2023	May 31, 2022
Customer A	68%	52%
Customer B	12%	13%
Customer C	-	13%
	80%	78%